RED HOT Contributors


FDA tentatively approves Eagle Pharma's cancer drug


(Reuters) – Eagle Pharmaceuticals Inc said on Friday that the U.S. Food and Drug Administration tentatively approved its injectable drug to treat a most common type of lung cancer and a cancer of mesothelial tissue.

The drug, Pemfexy, is a diluted version of Eli Lilly and Co’s top-selling oncology treatment, Alimta, which raked in sales of $2.28 billion in 2016.

A tentative approval means the drug is not eligible for marketing in the United States because of existing patent protections.

Reporting by Divya Grover in Bengaluru; Editing by Sriraj Kalluvila

Our Standards:The Thomson Reuters Trust Principles.


We Support OUR Contributors

Get Our Newsletter

 Receive podcast updates
Exclusive insights
Patient Engagement Tips from industry experts
We hate SPAM as much as you do and promise to keep your email address safe.
  • Subscribe to the Podcast